Credit Suisse’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-200,000
| Closed | -$784K | – | 3202 |
|
|
2023
Q3 | $784K | Buy |
200,000
+19,480
| +11% | +$133K | ﹤0.01% | 2436 |
|
|
2023
Q2 | $181K | Sell |
180,520
-751
| -0.4% | -$2.23K | ﹤0.01% | 3107 |
|
|
2023
Q1 | $655K | Sell |
181,271
-2,648
| -1% | -$40.9K | ﹤0.01% | 2586 |
|
|
2022
Q4 | $5.92M | Buy |
183,919
+410
| +0.2% | +$16.2K | 0.01% | 1201 |
|
|
2022
Q3 | $7.67M | Sell |
183,509
-227
| -0.1% | -$10.4K | 0.01% | 1033 |
|
|
2022
Q2 | $7.75M | Sell |
183,736
-122
| -0.1% | -$5.66K | 0.01% | 1039 |
|
|
2022
Q1 | $12.5M | Buy |
183,858
+5,534
| +3% | +$461K | 0.01% | 940 |
|
|
2021
Q4 | $21.6M | Buy |
178,324
+12,778
| +8% | +$2.16M | 0.01% | 1055 |
|
|
2021
Q3 | $23.3M | Buy |
165,546
+10,760
| +7% | +$2.13M | 0.01% | 1020 |
|
|
2021
Q2 | $42.5M | Buy |
154,786
+5,357
| +4% | +$1.35M | 0.02% | 771 |
|
|
2021
Q1 | $32M | Buy |
149,429
+14,153
| +10% | +$3.91M | 0.02% | 919 |
|
|
2020
Q4 | $32.7M | Buy |
135,276
+9,807
| +8% | +$1.21M | 0.02% | 904 |
|
|
2020
Q3 | $13.2M | Buy |
125,469
+22
| +0% | +$2K | 0.01% | 1225 |
|
|
2020
Q2 | $12.3M | Buy |
125,447
+50,441
| +67% | +$4.41M | 0.01% | 1203 |
|
|
2020
Q1 | $5.63M | Buy |
75,006
+15,368
| +26% | +$1.46M | ﹤0.01% | 1484 |
|
|
2019
Q4 | $4.84M | Buy |
59,638
+1,473
| +3% | +$165K | ﹤0.01% | 1904 |
|
|
2019
Q3 | $7.1M | Buy |
58,165
+3,051
| +6% | +$419K | 0.01% | 1515 |
|
|
2019
Q2 | $9.9M | Sell |
55,114
-74
| -0.1% | -$12K | 0.01% | 1320 |
|
|
2019
Q1 | $8.83M | Buy |
55,188
+54
| +0.1% | +$10.7K | 0.01% | 1311 |
|
|
2018
Q4 | $14.3M | Buy |
55,134
+10,720
| +24% | +$2.16M | 0.01% | 966 |
|
|
2018
Q3 | $10.8M | Buy |
44,414
+22,406
| +102% | +$5.86M | 0.01% | 1209 |
|
|
2018
Q2 | $5.19M | Buy |
+22,008
| New | +$6.42M | 0.01% | 1710 |
|
Other funds holding EVLO
Credit Suisse's EVLO Position: Q4 2023 in Review
Credit Suisse sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 200,000 shares — an estimated $784K sold.
Credit Suisse first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $42.5M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Credit Suisse reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Credit Suisse sold 200,000 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $784K.
- Credit Suisse first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Credit Suisse's Evelo Biosciences, Inc. Common Stock position peaked at $42.5M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.